Page de couverture de Clinic Realities vs. Trial Data: Post-Endocrine HER2-Low Care — Dr. Jason Mouabbi & Dr. Michelina Cairo

Clinic Realities vs. Trial Data: Post-Endocrine HER2-Low Care — Dr. Jason Mouabbi & Dr. Michelina Cairo

Clinic Realities vs. Trial Data: Post-Endocrine HER2-Low Care — Dr. Jason Mouabbi & Dr. Michelina Cairo

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

What happens when an MD Anderson breast oncology investigator Dr. Mouabbi sits down with a high-volume community oncologist Dr. Cairo, who now treats the same patients the trials were written for? Over one fast-moving hour, they chart the collapse of the old HER2 binary, weigh DESTINYBreast 04 against 06, and admit that practicing oncologists still hesitate to jump straight from endocrine therapy to trastuzumab deruxtecan (TDXd) when trusty capecitabine is sitting on the shelf. They swap war stories about persuading pathology to report “ultralow” staining, debate whether any historical 1+ slide is enough to warrant an ADC, and reveal why “whichever ADC you give first is going to be your best ADC.” The conversation converges into ILD pragmatics, that is, community clinicians, it seems, aren’t the least bit afraid before landing on a new term the duo coined on air: “endocrine dynamics,” that is, the art of cycling back to hormones once the aggressive clone is beaten down by an ADC.


Highlights you’ll hear: the trial-by-trial evolution from DB04 to DB06 and why ultralow tumors now matter; capecitabine versus the allure of earlier ADCs; ultralow testing bottlenecks and the coming ASCOCAP guideline shakeup; sequencing philosophies (sandwich vs back-to-back) and their payload implications; real-world ILD management that’s less daunting than advertised; and, at the close, a playful wager on whether we’ll soon treat every HR-positive case as “ADC-eligible” until true zero is finally defined.


🎧 Listen, share, and subscribe for more CHM Conversations that fuse bigtrial evidence with the front lines


#BreastCancer #HER2Low #Ultralow #TDXd #ADCSequencing #OncologyPodcast #CHMConversations



Thanks for listening!


Our podcasts are also available on:

• Youtube - youtube.com/@CommunityHealthMedia

• Amazon Music - amazn.so/chm-podcast

• Apple Podcast - podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - castbox.fm/vh/6735434

• Goodpods - goodpods.com/profile/chm-111066

• iHeartRadio - iheart.com/podcast/291542082

• Pocket Casts - pca.st/3ncdh11o



Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.


We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.


We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts


Learn more about us here - https://communityhealth.media

Pas encore de commentaire